

RESEARCH ARTICLE

Incidence and Mortality of Bladder Cancer and their Relationship with Development in Asia

Reza Pakzad^{1,2}, Abdollah Mohammadian-Hafshejani^{1,3}, Mahdi Mohammadian⁴, Iraj Pakzad^{5,6}, Saeid Safiri⁷, Salman Khazaei⁸, Hamid Salehiniya^{1,9*}

Abstract

Background: Over the past decade, bladder cancer was associated with a significant increase. Given the importance of the impact of socioeconomic status on the distribution of cancer incidence and mortality, and the need to information on these parameters for prevention planning, the aim of this study was to evaluate data for bladder cancer and their relationship with human development index (HDI) and its components in Asia in 2012. **Materials and Methods:** The study was conducted based on data from the world data of cancer and the World Bank (including the HDI and its components). The incidence and mortality rates were drawn for Asian countries. To analyze data, correlation tests between incidence and death rates, and HDI and its components were employed with a significance level of 0.05 using SPSS software. **Results:** A total incidence of 696,231 cases (68.7% in males and 31.3% in females, sex ratio of 2.19:1) and 524,465 deaths (67.0% in men and 32.9% in women, sex ratio was 2.03:1) were recorded in Asian countries in 2012. Correlation between HDI and standardized incidence rate was 0.241 overall ($p=0.106$), 0.236 in men ($p=0.114$) and -0.250 in women ($p=0.094$). Also between HDI and standardized mortality rate 0.025 ($p=0.871$) in men 0.118 ($p=0.903$) and in women 0.014 ($p=0.927$). **Conclusions:** Bladder cancer incidence is higher in developed countries, but the rate is declining, and in less developed and developing countries it is growing. There was no statistically significant correlation between the standardized incidence rate of bladder cancer and the HDI and its dimensions in Asia, except for the level of education.

Keywords: Bladder cancer - incidence - mortality - HDI - Asia - development

Asian Pac J Cancer Prev, 16 (16), 7365-7374

Introduction

Cancer is a major burden of disease and public health concern in world (Keyghobadi et al., 2014; Razi et al., 2014). Among cancers, bladder cancer is the seventh most common cancer in men, while seventeenth most common cancer in women worldwide. It is considered the most common urinary tract and genital cancer (Akbari et al., 2008; Burger et al., 2013; Ferlay et al., 2015). Over the past decade, bladder cancer was associated with a significant increase, so that in 2002, over 357,000 cases of bladder cancer were reported in the world (Murta-Nascimento et al., 2007). However, from almost 430,000 cases in 2012 in the world, 165,000 people had died (Ferlay et al., 2013; Lyon, 2013; Malats and Real, 2015). The incidence of bladder cancer in men is three to four times higher than in women. Seven percent of all new cancer cases were men, but only women include 2% of new cases of the cancer

(Ahmadi et al., 2012).

Distribution of cancer in the world is different. Two thirds of new cases of bladder cancer occur in developing countries (Ploeg et al., 2009; Yavari et al., 2009). The difference in the incidence of bladder cancer in the world may be not only for the causal factors, but also due to the cancer registry systems (Malats and Real, 2015). However, it is predicted cancer incidence in developing countries will increase in the future, and a greater burden is devoted to the disease (Ploeg et al., 2009). There are several causal factors for bladder cancer, but two main causes of the cancer are smoking and occupational exposure to chemicals in the environment (Kogevinas et al., 2003; Ploeg et al., 2009; Yavari et al., 2009). In terms of morphology, in developed countries, about 90% of all bladder cancer cases are transitional cell carcinoma, resulting from f the smoke and chemicals, 5% squamous cell carcinomas, and 2% adenocarcinomas. However,

¹Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, ⁹Minimally Invasive Surgery Research Center, Iran University of Medical Sciences, Tehran, ²Department of Epidemiology, Faculty of Health, ⁵Department of Microbiology, Medical School, ⁶Clinical Microbiology Research center, Ilam University of Medical Sciences, Ilam, ³Department of Social Medicine, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, ⁴Isfahan University of Medical Sciences, Isfahan, ⁷Department of Public Health, School of Nursing and Midwifery, Maragheh University of Medical Sciences, Maragheh, ⁸Department of Epidemiology and Biostatistics, School of Public Health, Hamadan University of Medical Sciences, Hamadan, Iran
*For correspondence: alesaleh70@yahoo.com

in developing countries, 75% cases are squamous cell carcinomas, due to exposure to parasites, such as *Schistosoma haematobium* (Kirkali et al., 2005; Creel, 2007), which is responsible for the incidence of most cases in Egypt, where the highest incidence of bladder cancer in the world (37.1 per 100,000) was observed (Ploeg et al., 2009). It is estimated that the mortality rate for bladder cancer is 10 per 100,000 for men and 2.4 thousand per 100,000 for women. Although the mortality rate for the cancer depends on the stage of cancer and development levels of a region. It is shown that the mortality rate for bladder cancer in developed countries has a decreasing trend in the last half century (Yavari et al., 2009). Incidence and prevalence of bladder cancer increases with age, so that the peak its incidence is the seventh and eighth decades of life (Malats and Real, 2015). Although screening is not recommended for bladder cancer, studies have shown that the use of Hematuria home screening can reduce deaths from bladder cancer (Messing et al., 1995; Botteman et al., 2003). Studies have shown that the incidence and survival of bladder cancer is so strongly influenced by socioeconomic status. In other words, bladder cancer survival remarkably decreases in low socioeconomic status (Adler and Ostrove, 1999). It is also shown that people with high knowledge level expose lower to bladder cancer risk factors, including smoking. As a result they less suffer from bladder cancer (Yang et al., 2010). Also, in those with high education and income, better bladder cancer survival is observed (Mackillop et al., 1997; Hussain et al., 2008).

To investigate the status of countries, indicators are defined. One of the indicators is Human Development Index (HDI). The index assesses the position of a country in three basic aspects of development, and is a composite index of longevity, knowledge, and standard of living. Longevity is measured with life expectancy at birth, knowledge with potential years of education, and adequate standard of living with income or per GDP capita (Malik, 2013).

A number of studies showed the effective role of HDI in cancer incidence and mortality (Ghoncheh et al., 2015). There was no a comprehensive study on bladder cancer incidence and mortality in Asia. It is necessary to know information on incidence and mortality for health planning and research activities. Considering the possible role, the aim of this study was to evaluate the incidence and mortality of the cancer, and their relationship with HDI and its components in Asia in 2012.

Materials and Methods

This study was an ecologic study in Asia for assessment the correlation between age-specific incidence and mortality rate (ASR) with Human Development Index (HDI) and its details that include: Life expectancy at birth, Mean years of schooling and Gross national income per capita. Data about the age-specific incidence and mortality rate (ASR) for every Asian counter for year 2012 get from global cancer project that available in (<http://globocan.iarc.fr/Default.aspx>) and Human Development Index (HDI) from Human Development Report 2013 (Malik,

2013) that include information about HDI and its details for every country in the word for year 2012.

Method of estimate the age-specific Incidence and mortality rates in global cancer project by international agency for research on cancer

Age-specific incidence rate estimate

The methods of estimation are country specific and the quality of the estimation depends upon the quality and on the amount of the information available for each country. In theory, there are as many methods as countries, and because of the variety and the complexity of these methods, an overall quality score for the incidence and mortality estimates combined is almost impossible to establish. However an alphanumeric scoring system which independently describes the availability of incidence and mortality data has been established at the country level. The combined score is presented together with the estimates for each country with an aim of providing a broad indication of the robustness of the estimation.

The methods to estimate the sex- and age-specific incidence rates of cancer for a specific country fall into one of the following broad categories, in priority order:

- 1- Rates projected to 2012 (38 countries)-2- Most recent rates applied to 2012 population (20 countries)-3-Estimated from national mortality by modelling, using incidence mortality ratios derived from recorded data in country-specific cancer registries (13 countries)-4- Estimated from national mortality estimates by modelling, using incidence mortality ratios derived from recorded data in local cancer registries in neighboring countries (9 European countries)-5-Estimated from national mortality estimates using modelled survival (32 countries)-6- Estimated as the weighted average of the local rates (16 countries)-7- One cancer registry covering part of a country is used as representative of the country profile (11 countries)-8-Age/sex specific rates for "all cancers" were partitioned using data on relative frequency of different cancers (by age and sex) (12 countries)-9- The rates are those of neighboring countries or registries in the same area (33 countries) (Ferlay et al., 2013; Lyon, 2013; Ferlay et al., 2015).

Age-specific mortality rate estimate

Depending of the degree of detail and accuracy of the national mortality data, six methods have been utilized in the following order of priority:

- 1-Rates projected to 2012 (69 countries)-2- Most recent rates applied to 2012 population (26 countries)-3- Estimated as the weighted average of regional rates (1 country)-4- Estimated from national incidence estimates by modelling, using country-specific survival (2 countries)-5-Estimated from national incidence estimates using modelled survival (83 countries)-6-The rates are those of neighboring countries or registries in the same area (3 countries) (Ferlay et al., 2013; Lyon, 2013; Ferlay et al., 2015).

Human Development Index (HDI)

Human Development Index (HDI), a composite measure of indicators along three dimensions: life

expectancy, educational attainment and command over the resources needed for a decent living. All groups and regions have seen notable improvement in all HDI components, with faster progress in low and medium HDI countries. On this basis, the world is becoming less unequal. Nevertheless, national averages hide large variations in human experience. Wide disparities remain within countries of both the North and the South, and income inequality within and between many countries has been rising (Malik, 2013).

Statistical analysis

In this study, we use of correlation bivariate method for assessment the correlation between age-specific incidence and mortality rate (ASR) with Human Development Index (HDI) and its details that include: Life expectancy at birth, Mean years of schooling and Gross national income (Burger et al.) per capita. Statistical significance was assumed if $P < 0.05$. All reported P-values are two-sided. Statistical analyses were performed using SPSS (Version 15.0, SPSS Inc).

Results

A total of 696231, bladder cancer cases were recorded in Asian countries in 2012. Overall, 478,069 cases (68.66%) were males, and 218,162 cases (31.34%) females. Sex ratio in Asia was 2.19. The five countries with the highest number of new patients were china (404,996 cases), Japan (107,898 cases), India (63,097 cases), Korea (31,269 cases), and Vietnam (14,203 cases), respectively. The countries included a total of 621,463 cases (8.26%) in Asia.

Among Asian countries, five countries with the highest standardized incidence rates of the cancer were Korea with 41.8 per 100,000, Mongolia with 32.5 per 100,000, Japan with 29.9 per 100,000, China with 22.7 per 100,000, and Tajikistan with 21.7 per 100,000, respectively. Five countries with the lowest standardized incidence rates of the cancer were Timor-Leste with 2.3 per 100,000, Kuwait with 2.6 per 100,000, Indonesia with 2.8 per 100,000, Pakistan with 3 per 100,000, and Thailand with 3.1 per 100,000, respectively. The number, crude, and standardized incidence rates of the cancer in Asian countries based on sex are presented in Table 1. Countries in the table are sorted from high to low based on the standardized incidence rate. The countries with the highest and lowest standardized incidence rate in both sexes are observable in Table 1 and Figure 1.

However, in 2012, in Asia, the number of deaths due to bladder cancer was 524,465 cases, 351,466 cases (67.01%) in men and 172,999 cases (32.92%) in women. The sex ratio (male to female) of mortality was equal to 2.03. The five countries with the highest number of deaths were china (325,166 cases), India (59,041 cases), Japan (52,326 cases), Vietnam (12,931 cases), and Korea (10,746 cases), respectively. The countries included a total of 460,210 cases (87.74%) of the total mortality in Asia.

In Asian countries, 5 countries with the highest standardized mortality rates from the cancer were Mongolia with 25.3 per 100,000, Tajikistan with 19.8 per

100,000, Kyrgyzstan with 19.6 per 100,000, Kazakhstan with 18 per 100,000, and China with 17.9 per 100,000, respectively. Five countries with the lowest standardized mortality rates from the cancer were Kuwait with 1.6 per 100,000, Lao PDR with 2.2 per 100,000, Timor-Leste with 2.3 per 100,000, Thailand with 2.5 per 100,000, and Indonesia with 2.5 per 100,000, respectively. The number, crude, and standardized mortality rates of the cancer in Asian countries based on sex are presented in Table 2. Countries in the table are sorted from high to low based on the standardized mortality rate. The countries with the highest and lowest standardized mortality rate are observable in both sexes in Table 2 and Figure 1.

In Table 3, amounts related to HDI and its components for each of the Asian countries (sorted based on HDI) is shown. Accordingly, Asian countries are classified according to HDI as follows: three countries in the very high category, four countries in high, thirty five countries




Figure 1. Standardized and Incidence Rates of Mortality of Bladder Cancer in twenty Asian Countries with the Highest Standardized and Incidence Rates in 2012




Figure 2. Correlation between HDI and Standardized Incidence of Bladder Cancer in Asia in 2012

Table 1. Number, crude and standardized incidence rate of bladder cancer in Asian countries in 2012 (Sorted by age standardized rates from highest to lowest)

Bladder- Estimated incidence, all ages: both sexes				Bladder- Estimated incidence, all ages: male				Bladder- Estimated incidence, all ages: female			
POPULATION	Numbers	Crude Rate	ASR (W)	POPULATION	Numbers	Crude Rate	ASR (W)	POPULATION	Numbers	Crude Rate	ASR (W)
Lebanon	777	18.1	16.6	Lebanon	618	29.5	29.1	Lebanon	159	7.2	6.1
Turkey	10757	14.4	15.2	Turkey	9396	25.3	28.7	Iraq	495	3.0	5.2
Israel	1414	18.4	12.6	Armenia	495	34.2	27.3	Israel	281	7.2	4.3
Armenia	554	17.8	12.3	Israel	1133	29.8	22.7	Turkey	1361	3.6	3.5
Iraq	1840	5.5	11.4	Iraq	1345	7.9	19.9	Syrian Arab Republic	248	2.4	3.5
Syrian Arab Republic	1300	6.2	9.6	Syrian Arab Republic	1052	9.8	16.1	Iran, Islamic Republic of	1066	2.9	3.4
Iran, Islamic Republic of	5343	7.1	8.3	Kazakhstan	945	12.0	14.9	Kuwait	14	1.2	2.7
State of Palestine	153	3.6	7.6	Iran, Islamic Republic of	4277	11.2	13.2	State of Palestine	27	1.3	2.5
Jordan	269	4.2	7.1	State of Palestine	126	5.8	13.1	Korea, Democratic Republic of	495	4.0	2.5
Kazakhstan	1146	7.0	6.7	Jordan	235	7.1	12.3	United Arab Emirates	13	0.5	2.4
Bahrain	41	3.0	6.3	Japan	16755	27.2	9.8	Oman	15	1.3	2.3
Japan	22042	17.4	5.6	Bahrain	35	4.1	9.6	Japan	5287	8.1	2.2
Kuwait	75	2.6	5.5	Korea, Republic of	3305	13.6	9.6	Armenia	59	3.6	2.2
Qatar	32	1.7	5.3	Georgia	279	13.8	8.4	Bahrain	6	1.2	2.1
Korea, Republic of	4097	8.4	5.2	Korea, Democratic Republic of	975	8.1	7.9	Qatar	2	0.4	1.9
Oman	73	2.5	4.8	Kuwait	61	3.5	7.1	Kazakhstan	201	2.4	1.8
Korea, Democratic Republic of	1470	6.0	4.6	Singapore	262	9.9	7.0	Jordan	34	1.1	1.8
United Arab Emirates	75	0.9	4.3	Qatar	30	2.0	6.7	Singapore	76	2.9	1.8
Singapore	338	6.4	4.3	Oman	58	3.4	6.7	Korea, Republic of	792	3.2	1.7
Georgia	331	7.7	4.1	Timor-Leste	16	2.6	6.6	Pakistan	947	1.1	1.6
Malaysia	890	3.0	3.7	Malaysia	718	4.8	6.1	Turkmenistan	33	1.3	1.5
Saudi Arabia	596	2.1	3.6	Turkmenistan	96	3.8	5.9	Afghanistan	109	0.7	1.5
Timor-Leste	18	1.5	3.5	Kyrgyzstan	97	3.6	5.8	China		2.1	1.4
Turkmenistan	129	2.5	3.5	Indonesia	5705	4.7	5.8	Cambodia	80	1.1	1.4
Pakistan	3967	2.2	3.4	Saudi Arabia	505	3.2	5.7	Malaysia	172	1.2	1.4
Afghanistan	458	1.4	3.3	United Arab Emirates	62	1.1	5.2	Tajikistan	31	0.9	1.3
Indonesia	6978	2.9	3.2	Tajikistan	92	2.6	5.1	Saudi Arabia	91	0.7	1.2
Tajikistan	123	1.7	3.0	Afghanistan	349	2.0	5.1	Myanmar	267	1.1	1.2

Table 1. Number, crude and standardized incidence rate of bladder cancer in Asian countries in 2012 (Sorted by age standardized rates from highest to lowest)

Bladder- Estimated incidence, all ages: both sexes				Bladder- Estimated incidence, all ages: male				Bladder- Estimated incidence, all ages: female			
POPULATION	Numbers	Crude Rate	ASR (W)	POPULATION	Numbers	Crude Rate	ASR (W)	POPULATION	Numbers	Crude Rate	ASR (W)
China	55486	4.1	3.0	Pakistan	3020	3.3	5.1	Azerbaijan	70	1.5	1.2
Kyrgyzstan	112	2.1	2.8	China	41993	5.9	4.8	Thailand	616	1.7	1.2
Azerbaijan	259	2.7	2.7	Azerbaijan	189	4.0	4.7	Indonesia	1273	1.0	1.1
Thailand	2537	3.6	2.7	Thailand	1921	5.6	4.5	Uzbekistan	108	0.8	0.9
Uzbekistan	461	1.6	2.3	Uzbekistan	353	2.5	3.8	Lao PDR	20	0.6	0.9
Cambodia	203	1.4	2.2	Maldives	5	3.1	3.8	Nepal	101	0.6	0.9
Myanmar	870	1.8	2.1	Yemen	166	1.3	3.6	Georgia	52	2.3	0.9
Lao PDR	83	1.3	2.1	Lao PDR	63	2.0	3.5	Philippines	310	0.6	0.9
Maldives	5	1.5	2.0	Nepal	295	1.9	3.3	Bhutan	2	0.6	0.9
Nepal	396	1.3	2.0	Brunei	7	3.4	3.2	Sri Lanka	105	1.0	0.7
Sri Lanka	484	2.3	1.8	Myanmar	603	2.5	3.2	Timor-Leste	2	0.3	0.7
Yemen	179	0.7	1.8	Sri Lanka	379	3.6	3.1	India	3122	0.5	0.6
India	16273	1.3	1.6	Cambodia	123	1.7	3.1	Bangladesh	319	0.4	0.6
Brunei	7	1.7	1.6	India	13151	2.0	2.7	Kyrgyzstan	15	0.5	0.6
Bangladesh	1672	1.1	1.6	Bangladesh	1353	1.8	2.5	Viet Nam	218	0.5	0.5
Philippines	989	1.0	1.5	Philippines	679	1.4	2.3	Mongolia	4	0.3	0.3
Mongolia	23	0.8	1.1	Mongolia	19	1.4	2.2	Yemen	13	0.1	0.3
Viet Nam	905	1.0	1.1	Viet Nam	687	1.5	1.8	Brunei	0	0.0	0.0
Bhutan	5	0.7	1.0	Bhutan	3	0.8	1.1	Maldives	0	0.0	0.0

in the middle category, three countries in low, and one in the unknown category.

Standardized incidence rate and HDI

A negative correlation was seen between the standardized incidence rate of bladder cancer and HDI about 0.241. This association was not statistically significant ($p=0.106$). There was a positive correlation between the standardized incidence rate and life expectancy at birth about 0.103 ($p=0.498$), positive correlation between the standardized incidence rate and mean years of schooling about 0.405 ($p=0.005$), and negative correlation between the level of income per each person of the population and the standardized incidence rate equal to -0.031 ($p=0.838$). (Figure 2)

In men, a positive correlation of 0.236 was observed between the standardized incidence rate of bladder cancer and HDI. It was not statistically significant ($p=0.114$). There was a positive correlation between the standardized incidence rate and life expectancy at birth about 0.102 ($p=0.502$), a positive correlation between mean years of schooling and the standardized incidence rate about 0.410 ($p=0.005$), and negative correlation between the level of income per each person of the population and the standardized incidence rate equal to -0.044 ($p=0.774$).

In women, a negative correlation of -0.250 was observed between the standardized incidence rate of bladder cancer and HDI. It was not statistically significant ($p=0.094$). There was a positive correlation between the standardized incidence rate and life expectancy at birth about 0.092 ($p=0.545$), positive correlation between mean years of schooling and the standardized incidence rate about 0.419 ($p=0.04$), and negative correlation between the level of income per each person of the population and the standardized incidence rate equal to -0.015 ($p=0.923$).

The standardized mortality rate and HDI

There was between the standardized mortality rate for bladder cancer and HDI a negative correlation of 0.025 ($p=0.871$), expectancy at birth a negative correlation of -0.173 ($p=0.252$), mean years of schooling a negative correlation equal to -0.233 ($p=0.119$), and the level of income per each person of population a negative correlation of -0.213 ($p=0.155$). (Figure 3)

In men, there was between the standardized mortality rate for bladder cancer and HDI a negative correlation of 0.118 ($p=0.903$), expectancy at birth a negative correlation of 0.165 ($p=0.274$), mean years of schooling a positive correlation equal to 0.253 ($p=0.090$), and the level of income per each person of population a negative

Table 2. Number, Crude and Standardized Mortality Rates for Bladder Cancer in Asian Countries in 2012 (Sorted by age standardized rates from highest to lowest)

Bladder- Estimated mortality, all ages: both sexes				Bladder- Estimated mortality, all ages: male				Bladder- Estimated mortality, all ages: female			
POPULATION	Numbers	Crude Rate	ASR (W)	POPULATION	Numbers	Crude Rate	ASR (W)	POPULATION	Numbers	Crude Rate	ASR (W)
Turkey	4690	6.3	6.6	Turkey	4099	11.0	12.8	Iraq	275	1.6	2.9
Iraq	1016	3.0	6.3	Iraq	741	4.4	11.4	Lebanon	64	2.9	2.4
Lebanon	307	7.2	6.3	Armenia	221	15.3	11.3	Syrian Arab Republic	125	1.2	1.8
Armenia	248	8.0	5.0	Lebanon	243	11.6	11.0	Kuwait	7	0.6	1.6
Syrian Arab Republic	653	3.1	4.9	Syrian Arab Republic	528	4.9	8.3	Turkey	591	1.6	1.5
State of Palestine	74	1.7	3.9	State of Palestine	61	2.8	7.0	Iran, Islamic Republic of	453	1.2	1.4
Iran, Islamic Republic of	2280	3.0	3.5	Kazakhstan	366	4.7	6.1	State of Palestine	13	0.6	1.2
Jordan	121	1.9	3.2	Iran, Islamic Republic of	1827	4.8	5.5	Oman	7	0.6	1.2
Kazakhstan	447	2.7	2.6	Jordan	105	3.2	5.5	Afghanistan	73	0.5	1.1
Afghanistan	307	0.9	2.5	Timor-Leste	10	1.7	4.3	Korea, Democratic Republic of	256	2.0	1.1
Oman	34	1.2	2.5	Israel	227	6.0	3.9	Pakistan	571	0.6	1.0
Bahrain	11	0.8	2.4	Bahrain	9	1.1	3.9	Israel	77	2.0	0.9
Israel	304	4.0	2.2	Afghanistan	234	1.4	3.8	Armenia	27	1.6	0.9
Timor-Leste	11	0.9	2.2	Korea, Democratic Republic of	430	3.6	3.8	Jordan	16	0.5	0.9
Kuwait	26	0.9	2.1	Oman	27	1.6	3.4	Bhutan	2	0.6	0.9
Pakistan	2396	1.3	2.1	Georgia	112	5.5	3.1	Cambodia	47	0.6	0.9
Korea, Democratic Republic of	686	2.8	2.1	Kyrgyzstan	50	1.9	3.1	Bahrain	2	0.4	0.8
Indonesia	3599	1.5	1.7	Pakistan	1825	2.0	3.1	Myanmar	166	0.7	0.8
Qatar	7	0.4	1.6	Indonesia	2940	2.4	3.1	Turkmenistan	15	0.6	0.7
Turkmenistan	58	1.1	1.6	Turkmenistan	43	1.7	2.9	Tajikistan	16	0.4	0.7
Tajikistan	64	0.9	1.6	Tajikistan	48	1.4	2.8	Japan	2462	3.8	0.7
United Arab Emirates	18	0.2	1.5	Korea, Republic of	955	3.9	2.6	United Arab Emirates	3	0.1	0.7
Georgia	133	3.1	1.5	Kuwait	19	1.1	2.5	Kazakhstan	81	1.0	0.7
Kyrgyzstan	58	1.1	1.5	Japan	5168	8.4	2.4	China	6762	1.0	0.6
Japan	7630	6.0	1.4	Qatar	7	0.5	2.4	Korea, Republic of	375	1.5	0.6
Korea, Republic of	1330	2.7	1.4	Yemen	105	0.8	2.4	Nepal	64	0.4	0.6
Saudi Arabia	211	0.7	1.4	Saudi Arabia	178	1.1	2.3	Indonesia	659	0.5	0.6
China		2.0	1.4	China	20058	2.8	2.2	Thailand	312	0.9	0.6
Cambodia	121	0.8	1.4	Lao PDR	39	1.2	2.2	Lao PDR	12	0.4	0.5
Myanmar	542	1.1	1.3	Thailand	976	2.8	2.2	Uzbekistan	56	0.4	0.5
Lao PDR	51	0.8	1.3	Nepal	189	1.2	2.2	Azerbaijan	31	0.7	0.5
Thailand	1288	1.8	1.3	Azerbaijan	83	1.8	2.1	Saudi Arabia	33	0.3	0.5
Nepal	253	0.8	1.3	Cambodia	74	1.0	2.1	Singapore	20	0.8	0.4

Table 2. Number, , Crude and Standardized Mortality Rates for Bladder Cancer in Asian Countries in 2012 (Sorted by age standardized rates from highest to lowest)

				Bladder- Estimated mortality, all ages: male				Bladder- Estimated mortality, all ages: female			
POPULATION	Numbers	Crude Rate	ASR (W)	POPULATION	Numbers	Crude Rate	ASR (W)	POPULATION	Numbers	Crude Rate	ASR (W)
Azerbaijan	114	1.2	1.2	Myanmar	376	1.6	2.1	Philippines	138	0.3	0.4
Uzbekistan	231	0.8	1.2	Uzbekistan	175	1.3	2.0	Bangladesh	196	0.3	0.4
Yemen	113	0.4	1.2	United Arab Emirates	15	0.3	1.9	India	1859	0.3	0.4
Malaysia	264	0.9	1.1	Malaysia	221	1.5	1.9	Timor-Leste	1	0.2	0.4
Bangladesh	1016	0.7	0.9	India	7664	1.2	1.6	Malaysia	43	0.3	0.4
Singapore	75	1.4	0.9	Bangladesh	820	1.1	1.5	Georgia	21	0.9	0.3
India	9523	0.8	0.9	Singapore	55	2.1	1.5	Sri Lanka	47	0.4	0.3
Sri Lanka	216	1.0	0.8	Sri Lanka	169	1.6	1.4	Mongolia	4	0.3	0.3
Bhutan	4	0.5	0.7	Philippines	292	0.6	1.1	Kyrgyzstan	8	0.3	0.3
Philippines	430	0.4	0.7	Viet Nam	367	0.8	1.0	Viet Nam	119	0.3	0.3
Viet Nam	486	0.5	0.6	Brunei	2	1.0	0.9	Yemen	8	0.1	0.2
Mongolia	12	0.4	0.5	Mongolia	8	0.6	0.8	Brunei	0	0.0	0.0
Brunei	2	0.5	0.5	Bhutan	2	0.5	0.7	Maldives	0	0.0	0.0
Maldives	1	0.3	0.3	Maldives	1	0.6	0.6	Qatar	0	0.0	0.0

Table 3. Human Development Index and its Components in Asian Countries in 2012

	POPULATION	Human Development Index(HDI)	Life expectancy at birth	Mean Year of schooling	Gross national income (Burger et al.) per capita
Very high human development	Japan	0.912	83.6	11.6	32545
	Korea, Republic of	0.909	80.7	11.6	28231
	Israel	0.9	81.9	11.9	26224
	Singapore	0.895	81.2	10.1	52613
	Brunei	0.855	78.1	8.6	45690
	Qatar	0.834	78.5	7.3	87478
	United Arab Emirates	0.818	76.7	8.9	42716
High human development	Bahrain	0.796	75.2	9.4	19154
	Kuwait	0.79	74.7	6.1	52793
	Saudi Arabia	0.782	74.1	7.8	22616
	Malaysia	0.769	74.5	9.5	13676
	Kazakhstan	0.754	67.4	10.4	10451
	Georgia	0.745	73.9	12.1	5005
	Lebanon	0.745	72.8	7.9	12364
	Iran, Islamic Republic of	0.742	73.2	7.8	10695
	Azerbaijan	0.734	70.9	11.2	8153
	Oman	0.731	73.2	5.5	24092
	Armenia	0.729	74.4	10.8	5540
	Turkey	0.722	74.2	6.5	13710
	Sri Lanka	0.715	75.1	9.3	5170

Table 3. Human Development Index and its Components in Asian Countries in 2012

	POPULATION	Human Development Index(HDI)	Life expectancy at birth	Mean Year of schooling	Gross national income (Burger et al.) per capita
Medium human development	Jordan	0.7	73.5	8.6	5272
	China	0.699	73.7	7.5	7945
	Turkmenistan	0.698	65.2	9.9	7782
	Thailand	0.69	74.3	6.6	7722
	Maldives	0.688	77.1	5.8	7478
	Mongolia	0.675	68.8	8.3	4245
	State of Palestine	0.67	73	8	3359
	Philippines	0.654	69	8.9	3752
	Uzbekistan	0.654	68.6	10	3201
	Syrian Arab Republic	0.648	76	5.7	4674
	Indonesia	0.629	69.8	5.8	4154
	Kyrgyzstan	0.622	68	9.3	2009
	Tajikistan	0.622	67.8	9.8	2119
	Viet Nam	0.617	75.4	5.5	2970
	Iraq	0.59	69.6	5.6	3557
	Timor-Leste	0.576	62.9	4.4	5446
	India	0.554	65.8	4.4	3285
	Cambodia	0.543	63.6	5.8	2095
	Lao PDR	0.543	67.8	4.6	2435
Bhutan	0.538	67.6	2.3	5246	
Low human development	Bangladesh	0.515	69.2	4.8	1785
	Pakistan	0.515	65.7	4.9	2566
	Myanmar	0.498	65.7	3.9	1 817
	Nepal	0.463	69.1	3.2	1137
	Yemen	0.458	65.9	5.3	928
	Afghanistan	0.374	49.1	3.1	1000
Other countries or territories	Korea, Democratic People's Rep. of	-	-	-	-




Figure 3. Correlation between HDI and Standardized Mortality Rates for bladder Cancer in Asia in 2012

correlation of 0.223 (p=0.136).

In women, there was between the standardized mortality rate for bladder cancer and HDI a negative correlation of 0.014 (p=0.927), expectancy at birth a

negative correlation of 0.178 (p=0.237), mean years of schooling a positive correlation equal to 0.241(p=0.106), and the level of income per each person of population a negative correlation of 0.190 (p=0.207).

Discussion

Less than 35% of bladder cancer cases occur in Asia. Given that more than 60 percent of people in the world are in Asia, and most countries in the region are developing, it is expected that bladder cancer is associated with a significant increase in the continent. Therefore, health macro policies to deal with this cancer in the future are an important need (Ferlay et al., 2013; Lyon, 2013; Keyghobadi et al., 2014).

Our results showed that most standardized incidence rate of bladder cancer was related to the countries such as Republic of Korea, Mongolia, Japan, China, and Tajikistan. The countries had middle and high HDI. However, in our study, no strong correlation was found between HDI and incidence of bladder cancer. Other studies have shown that

there was a significant difference the incidence of bladder cancer in higher HDI countries than low HDI countries, but a little difference was observed in the mortality rate between the two groups of countries (Bray et al., 2012). The incidence of bladder cancer rises due to higher exposure to causal factors such as tobacco and chemicals industries, along with development (Burger et al., 2013).

The incidence of bladder cancer in the whole of Asia is three to four times less than European and American countries (Ferlay et al., 2013; Lyon, 2013). It is shown that the incidence and deaths from bladder cancer is declining in Europe and North America, while its incidence is increasing in Asian countries (Ploeg et al., 2009). This is due to shifting in smoking consumption from developed countries to developing countries and less developed, so that in North America and European countries in the early and mid-twentieth century, smoking has declined in both men and women. In the late twentieth century, smoking in less developed countries had significantly increased in men and women (Lopez et al., 1994; Mackay and Eriksen, 2002; Consortium, 2004; Delclos and Lerner, 2008; Razi et al., 2014). The justification for this is that in the last half century, consumption of hazardous industrial chemicals has been decreased in less developed countries, while it has been increased in developing countries in the same period (Delclos and Lerner, 2008; Ploeg et al., 2009).

In our study, no relationship was found between life expectancy as one of the dimensions of the HDI, and the standardized incidence and mortality rates. However, with increasing age, the incidence of bladder cancer increases. The peak of bladder cancer incidence occurs in 65 years, but in many developed countries life expectancy is less than from the peak. As a result, the risk of cancer is lower in them (Malats and Real, 2015). It is also necessary to note that the relationship between age and cancer could be due to previous exposure to risk factors for bladder cancer and their cumulative effect. Therefore, cancer usually occurs in old age.

One of the dimensions of HDI is the level of income, characterized by gross domestic product. In our study, there was no relationship between the income level, and standardized incidence and mortality rates. Studies have shown that cancer mortality is higher in low-income countries (Soerjomataram et al., 2012). A direct relationship was also observed between income level and bladder cancer survival rate. In other words, the survival rate increases with raising the income level (Mackillop et al., 1997). This may be due to better access to high quality health care. Ezzati revealed that smoking consumption is changing from countries with high income to low-middle income countries. Many lower and middle-income countries still are experiencing the first stage of the epidemiological transition of smoking (Ezzati and Lopez, 2003a; 2003b). Ward showed that even without regard to sex, in low-income countries smoking is twice than high income countries (Ward et al., 2004). Ploeg also indicated that in low-income countries, chemical consumption associated with bladder cancer has been increased, while in the same period, industrial use of such hazardous substances is declining in high-income countries. It is expected in the near future, the incidence

of bladder cancer will significantly increase in developing countries (Ploeg et al., 2009).

Another dimension of HDI was the level of education or awareness, characterized by mean years of schooling. In our study, there was no relationship between the education level and standardized death rate. However, a significant relationship was found between standardized incidence rate and the education level. Hussain has shown that the survival rate of bladder cancer is more in people with higher education (Hussain et al., 2008). It seems that in developed countries, better treatment, appropriate lifestyle, reducing smoking, the mechanization of industry and less use of hazardous chemicals, including aromatic amines, better access to health services, and reducing infectious diseases lead to decrease bladder cancer incidence and mortality. In developing and less developed countries, poor lifestyle, smoking, the use of traditional methods in the industry, excessive exposure to dangerous chemicals, and the lack of adequate infrastructure for the implementation of comprehensive cancer control programs lead to more likely bladder cancer incidence and die from it (Messing et al., 1995; Ploeg et al., 2009).

Bladder cancer incidence is higher in developed countries, but the rate is declining, and in less developed and developing countries it is growing. In contrast, bladder cancer mortality in developed countries is less and the survival of bladder cancer is more, while in developing and the less developed countries bladder cancer mortality is higher and survival is lower. There was no statistically significant correlation between the standardized incidence rate of bladder cancer, and the HDI and its dimensions, except for the level of education. No relationship was found between standardized mortality rate, and the HDI and its dimensions.

References

- Adler NE, Ostrove JM (1999). Socioeconomic status and health: what we know and what we don't. *Ann New York Academy Sci*, **896**, 3-15.
- Ahmadi M, Ranjbaran H, Amiri MM, et al (2012). Epidemiologic and socioeconomic status of bladder cancer in mazandaran province, northern Iran. *Asian Pac J Cancer Prev*, **13**, 5053-6.
- Akbari ME, Hosseini SJ, Rezaee A, et al (2008). Incidence of genitourinary cancers in the islamic republic of Iran: a survey in 2005. *Asian Pac J Cancer Prev*, **9**, 549-52.
- Botteman M, Pashos C, Redaelli A, et al (2003). The health economics of bladder cancer. *Pharmaco Economics*, **21**, 1315-30.
- Bray F, Jemal A, Grey N, et al (2012). Global cancer transitions according to the human development Index (2008-2030): a population-based study. *Lancet Oncol*, **13**, 790-801.
- Burger M, Catto JWF, Dalbagni G, et al (2013). Epidemiology and risk factors of urothelial bladder cancer. *European Urol*, **63**, 234-41.
- Consortium A (2004). Tobacco or health in the European Union: past, present and future, European Commission, Directorate General for Health and Consumer Protection.
- Creel P (2007). Bladder cancer: epidemiology, diagnosis, and treatment. *Semin Oncol Nurs*, **23**, 3-S10.
- Delclos GL, Lerner SP (2008). Occupational risk factors. *Scand J Urol Nephrol*, **42**, 58-63.

- Ezzati M, Lopez AD (2003a). Estimates of global mortality attributable to smoking in 2000. *Lancet*, **362**, 847-52.
- Ezzati M, Lopez AD (2003b). Measuring the accumulated hazards of smoking: global and regional estimates for 2000. *Tobacco Control*, **12**, 79-85.
- Ferlay J, Soerjomataram I, Dikshit R, et al (2015). Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer*, **136**, 359-86.
- Ferlay J, Soerjomataram I, Ervik M, et al (2013). GLOBOCAN 2012 v1. 0, cancer incidence and mortality worldwide: IARC CancerBase No. 11 [internet]. International Agency for Research on Cancer, Lyon. globocan. iarc. fr (accessed 10 October 2014).
- Ghoncheh M, Mohammadian-Hafshejani A, Salehiniya H (2015). Incidence and Mortality of Breast Cancer and their Relationship to Development in Asia. *Asian Pac J Cancer Prev*, **16**, 6081-7.
- Hussain SK, Lenner P, Sundquist J, et al (2008). Influence of education level on cancer survival in Sweden. *Ann Oncol*, **19**, 156-62.
- Keyghobadi N, Rafiemanesh H, Mohammadian-Hafshejani A, et al (2014). Epidemiology and trend of cancers in the province of kerman: southeast of iran. *Asian Pac J Cancer Prev*, **16**, 1409-13.
- Kirkali Z, Chan T, Manoharan M, et al (2005). Bladder cancer: Epidemiology, staging and grading, and diagnosis. *Urol*, **66**, 4-34.
- Kogevinas M, Mannetje At, Cordier S, et al (2003). Occupation and bladder cancer among men in Western Europe. *Cancer Causes Control*, **14**, 907-14.
- Lopez AD, Collishaw NE, Piha T (1994). A descriptive model of the cigarette epidemic in developed countries. *Tobacco Control*, **3**, 242.
- Lyon F (2013). International agency for research on cancer; 2013.
- Mackay J, Eriksen M (2002). The tobacco atlas (World Health Organization, Geneva).
- Mackillop W, Zhang-Salomons J, Groome P, et al (1997). Socioeconomic status and cancer survival in Ontario. *J Clin Oncol*, **15**, 1680-9.
- Malats N, Real FX (2015). Epidemiology of bladder cancer. *Hematol Oncol Clin North Am*, **29**, 177-89.
- Malik K (2013). Human development report 2013. the rise of the south: human progress in a diverse world. the rise of the south: human progress in a diverse world (March 15, 2013). UNDP-HDRO Human Development Reports.
- Messing EM, Young TB, Hunt VB, et al (1995). Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations. *Urol*, **45**, 387-97.
- Murta-Nascimento C, Schmitz-Drager BJ, Zeegers MP, et al (2007). Epidemiology of urinary bladder cancer: from tumor development to patient's death. *World J Urol*, **25**, 285-95.
- Ploeg M, Aben KK, Kiemeny LA (2009). The present and future burden of urinary bladder cancer in the world. *World J Urol*, **27**, 289-93.
- Razi S, Rafiemanesh H, Ghoncheh M, et al (2014). Changing trends of types of skin cancer in Iran. *Asian Pac J Cancer Prev*, **16**, 4955-8.
- Soerjomataram I, Lortet-Tieulent J, Parkin DM, et al (2012). Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. *Lancet*, **380**, 1840-50.
- Ward E, Jemal A, Cokkinides V, et al (2004). Cancer disparities by race/ethnicity and socioeconomic status. *CA Cancer J Clin*, **54**, 78-93.
- Yang Y, Wang J-J, Wang C-X, et al (2010). Awareness of tobacco-related health hazards among adults in China. *Biomed Environ Sci*, **23**, 437-44.
- Yavari P, Sadrolhefazi B, Mohagheghi M, et al (2009). A descriptive retrospective study of bladder cancer at a hospital in Iran (1973-2003). *Asian Pac J Cancer Prev*, **10**, 681-4.